NCT04203108 is a Phase 4 clinical trial of ATG in Hematopoietic Stem Cell Transplantation, sponsored by Nanfang Hospital, Southern Medical University.

Who is sponsoring NCT04203108?

NCT04203108 is sponsored by Nanfang Hospital, Southern Medical University.

What drugs are being tested in NCT04203108?

Interventions in NCT04203108: ATG, CsA, MTX, MMF.

What condition does NCT04203108 study?

NCT04203108 studies Hematopoietic Stem Cell Transplantation.

Is NCT04203108 still recruiting?

NCT04203108 is currently status unknown. Last updated 18 December 2019.

Last reviewed 2019-12-18 · How we verify

NCT04203108

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ATG in HLA-matched Sibling HSCT as GVHD Prophylaxis

Status unknown Phase 4 Last updated 18 December 2019

What this trial tests

Phase 4 trial testing ATG in Hematopoietic Stem Cell Transplantation in 266 participants. Status unknown.

Timeline

1 September 2019

Primary endpoint
31 August 2021

31 December 2022

Quick facts

Lead sponsor	Nanfang Hospital, Southern Medical University
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	266
Start date	1 September 2019
Primary completion	31 August 2021
Estimated completion	31 December 2022
Sites	1 location across China

Drugs / interventions tested

ATG — full drug profile →
CsA — full drug profile →
MTX — full drug profile →
MMF — full drug profile →

Conditions studied

Hematopoietic Stem Cell Transplantation — all drugs for Hematopoietic Stem Cell Transplantation →

Sponsor

Nanfang Hospital, Southern Medical University

Who can join

Adults 18 to 60, any sex, with Hematopoietic Stem Cell Transplantation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The protocols including ciclosporin A （CsA）+methotrexate (MTX) +mycophenolate Mofetil(MMF) have been widely used for graft-versus-host disease (GVHD) prophylaxis in allogeneic hematopoietic stem cell transplantation from HLA-matched sibling donor (MSD). Nevertheless, severe chronic graft-versus-host disease (cGVHD) remains an obstacle for MSD HSCT. A growing body of studies have suggested antithymocyte globulin (ATG) could reduce the incidence of cGVHD. This study is aim to evaluate the efficacy of a protocol that includes CsA, MTX, MMF and ATG in recipients of MSD HSCT.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adults.
Chakupurakal G, Freudenberger P, Skoetz N, Ahr H, et al · · 2023 · cited 8× · PMID 37341189 · DOI 10.1002/14651858.cd009159.pub3

Verify or expand the search:

Other trials of ATG

Trials testing the same drug.

NCT05669001 — A Study of TCD601 in de Novo Renal Transplant Recipients · Phase 2 · completed
NCT06108739 — ATG Plus Low-dose PT-Cy for GVHD Prevention · Phase 3 · terminated
NCT05917405 — Study Comparing the Efficacy of 2 RIC Regimens (Clofarabine vs Fludarabine) in Adults With AML Eligible to Allo-SCT · Phase 2 · recruiting
NCT05739630 — M-PTCy vs BuCy in Haploidentical HSCT for Acute Leukemia · Phase 2, PHASE3 · unknown
NCT05634915 — Clinical Study of rATG Individualized Administration in Haploidentical Hematopoietic Stem Cell Transplantation · Phase 4 · unknown

Other recruiting trials for Hematopoietic Stem Cell Transplantation

Currently open trials in the same condition.

NCT07400328 — Amimestrocel Injection for Preventing Severe Oral Mucositis in HSCT Patients · Phase 2 · recruiting
NCT07349498 — Cardiovascular Outcomes and Risk Evaluation Among Recipients of Hematopoietic Stem Cell Transplantation · recruiting
NCT07442513 — Comparison of Etamsylate Versus Placebo to Prevent Bleeding in HSCT · Phase 3 · recruiting
NCT06904053 — Metagenomics Next-generation Sequencing Approach to Detect Microbial DNA/RNA Overtime in Individuals Undergoing Hematopo · recruiting
NCT06708507 — Tissue-resident Immune Cell Subsets in aGVHD · recruiting

Other Nanfang Hospital, Southern Medical University trials

Trials by the same sponsor.

NCT07091994 — A Trial of Edaravone Dexborneol in Acute Ischemic Stroke With Active Malignancy · Phase 4 · not yet recruiting
NCT06444022 — hAESCs Prevent Acute Graft-versus-host Disease After Hematopoietic Stem Cell Transplantation · Phase 1 · withdrawn
NCT07537777 — Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted T · Phase 2 · not yet recruiting
NCT07481032 — Effect of Fufang Biejiaruangan Combined With Antiviral Therapy on the Incidence of Hepatocellular Carcinoma in Patients · NA · not yet recruiting
NCT07511894 — Beta-Blockers on the Efficacy of Neoadjuvant Immunotherapy for Gastric Cancer · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04203108 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Nanfang Hospital, Southern Medical University
Last refreshed: 18 December 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04203108.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing